The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Renews Call for Abolishing PMP Company Criteria
October 20, 2023
- Group of Academia-Originating Biotechs Boots Up in Japan
October 18, 2023
- Introduce Societal Value Premium for Regenerative Medicine Products: Consultant
October 17, 2023
- Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
- Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
- JMA Survey Finds Large Gap between Actual Drug Shortage, Industry Poll
October 11, 2023
- Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
- Eliminate Authorized Generics as They Hamper Competition: JMA
October 10, 2023
- Global CEOs Want Positive Sign from Japan, Sentiments Drive Decisions: EFPIA Chief
October 6, 2023
- Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
- Japan Drug Wholesalers’ Workforce Down 3% for 2nd Year: JPWA Survey
October 3, 2023
- Generic Use Rate Reaches Record 81.7% in April-June: JGA
September 29, 2023
- Assess Evaluation Methods for Innovative Medical Products: Science Council
September 28, 2023
- Ex-MHLW CMO Calls for Reasonable Pricing of Alzheimer’s Drugs
September 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
- Hiroyasu Kitagawa Named New Chief of Kyokai Kenpo
September 19, 2023
- JPMA Optimistic on New Minister’s Commitment on Boosting Innovation: Exec
September 15, 2023
- 4 Cell & Gene Therapies Represent 90% of Top 100 Bills in FY2022: Payer
September 8, 2023
- Single-Wholesaler Model Has No Merits for Hospitals: Hyogo Doctors Group
September 7, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…